US 11396544
Bispecific anti-CD28 × anti-CD22 antibodies and uses thereof
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11396544 (Bispecific anti-CD28 × anti-CD22 antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K39/39541, A61K39/39558